June 28 Company Quick Takes: FDA approves Pfizer's biosimilar of Avastin; plus Aimmune, PeptiDream, Novartis and Just/Teva
Pfizer gets second FDA-approved biosimilar with Zirabev approval
FDA approved Zirabev bevacizumab-bvzr from Pfizer Inc. (NYSE:PFE) to treat metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell long cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer. The mAb against vascular endothelial growth factor (VEGF) is a biosimilar of Genentech Inc.'s Avastin.
Aimmune seeks European approval for peanut allergy therapy
Aimmune Therapeutics Inc. (NASDAQ:AIMT) submitted an MAA to EMA for peanut allergy therapy AR101. The candidate is under FDA review, with the Allergenic Products Advisory Committee discussing the candidate's safety and efficacy on Sept. 13...